Microbiological profile of sputum in stable adult patients with bronchiectasis in the Dnipro region of Ukraine
Keywords:bronchiectasis, sputum, drug resistance, Pseudomonas aeruginosa
AbstractChronic respiratory tract infection and relapsing exacerbations worsen the quality and reduce the life expectancy of patients with bronchiectasis. This work aimed to identify the spectrum of pathogens and to determine their profile of antibiotic resistance in the sputum of patients with bronchiectasis in the Dnipro region. Sputum of 60 patients in a stable phase with confirmed bronchiectasis was a subject to microbiological examination and determination of antibiotic sensitivity according to generally accepted CLSI recommendations. According to the results of the study, it was found that 70% of patients have sputum colonization by pathogens in the stable phase of the disease, and the most common pathogens are Pseudomonas aeruginosa and Haemophilus influenzae, which is in line with the global trend. Haemophilus influenzae was sensitive to ampicillin, amoxicillin, amoxicillin/clavulanate, piperacillin/tazobactam, cefuroxime, ceftriaxone, cefotaxime, cefepime, ciprofloxacin, levofloxacin and moxifloxacin in a hundred percent of cases. However, more than half of the strains of Pseudomonas aeruginosa were resistant to one or more drugs with anti-Pseudomonas activity. In particular, the highest level of resistance was identified to such drugs as imipenem, aztreonam, ceftazidime. The problem of antibiotic resistance is alarming and once again indicates the need for the regular microbiological examination of the sputum of patients with bronchiectasis even in a stable phase for subsequent rational administration of antibacterial therapy.
Antomonov MYu. [Mathematical processing and analysis of biomedical data]. 2-e izd. Kyiv: Medinform; 2018. p. 579. Russian. Available from: https://www.olx.ua/.../antomonov-m-yu-monografya
Pertseva TO, Gashynova KYu, Dmytrychenko VV, et al. Bronchoectatic disease: the state of art and the clinical case. Medicni perspektivi. 2018;23(3):153-61. Ukrainian. doi: https://doi.org/10.26641/2307-0404.2018.3(part1).142360
Feshchenko YI, Gavrisyuk VK, Dziublyk IV, Dziublyk OYa. [Infectious exacerbation of chronic obstructive pulmonary disease: place and role of respiratory viral pathogens.]. Medicni perspektivi. 2019;24(4):30-35. doi: https://doi.org/10.26641/2307-0404.2019.4.189191
Vidal OS, Perea L, Cantó E, et al. Antimicrobial peptides and airway bacterial colonization in bronchiectasis. Eur Respir J. 2018;53(Suppl62):OA4948. doi: https://doi.org/10.1183/13993003.congress-2018.OA4948
Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society guideline for bronchiectasis in adults. Thorax. 2019;74(Suppl. 1):1-69. doi: https://doi.org/10.1136/thoraxjnl-2018-212463
Diaz AA, Young TP, Maselli DJ, et al. Bronchoarterial ratio in never-smokers adults: implications for bronchial dilation definition. Respirology. 2017;22(1):108-13. doi: https://doi.org/10.1111/resp.12875
Clinical and Laboratory Standards Institute. CLSI M100 S27:2017. Performance standard for antimicrobial susceptibility testing. 27th edn. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
Radovanovic D, Santus P, Blasi F, et al. A comprehensive approach to lung function in bronchiectasis. Respir Med 2018;145:120-9. doi: https://doi.org/10.1016/j.rmed.2018.10.031
Cornaglia G, Courcol R and Herrmann J-L. European Manual of Clinical Microbiology; 2012.
Lonni S, Chalmers JD, Goeminne PC, et al. Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Ann Am Thorac Soc 2015;12:1764-70. doi: https://doi.org/10.1513/AnnalsATS.201507-472OC
Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50:1700629. doi: https://doi.org/10.1183/13993003.00629-2017
Chandrasekaran R, Mac Aogain M, Chalmers JD, Elborn SJ, Chotirmall SH. Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. Bmc Pulmonary Medicine. 2018;18:14. doi: https://doi.org/10.1186/s12890-018-0638-0
Matuschek E, Brown DFJ and Kahlmeter G. Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. Clin Microbiol Infect. 2014;20:O255-66. doi: https://doi.org/10.1111/1469-0691.12373
Gashynova K, Suska K, Dmytrychenko V. Microbiome landscape and disease duration role in allergy in adult patients with bronchiectasis. Eur Respir J. 2019;54(Suppl63):PA2763. doi: https://doi.org/10.1183/13993003.congress-2019.PA2763
Polverino E, Rosales-Mayor E, Benegas M. Pneumonic and non-pneumonic exacerbations in bronchiectasis: clinical and microbiological differences. J Infect. 2018;77:99-106. doi: https://doi.org/10.1016/j.jinf.2018.04.006
Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014;189:576-85. doi: https://doi.org/10.1164/rccm.201309-1575OC
How to Cite
Copyright (c) 2020 Medicni perspektivi (Medical perspectives)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.